NAMS: Testosterone Patches Treat Low Sexual Desire in Surgically Menopausal Women
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




NAMS: Testosterone Patches Treat Low Sexual Desire in Surgically Menopausal Women

By Jerry Ingram

MIAMI BEACH, FL -- September 22, 2003 -- Treatment with a transdermal testosterone patch significantly increased sexual desire and sexual activity in women with hypoactive sexual desire disorder stemming from surgical removal of both ovaries, according to research from a phase II study.

These findings were presented here on September 19th at the 14th Annual Meeting of the North American Menopausal Society.

"Associated with the removal of the ovaries is about a 50% drop across the board in the amount of testosterone that's being produced. So the study was designed to test the delivery of testosterone through a transdermal patch to bring the testosterone levels up into the normal young female range, and to see if that replacement decreased the problems with libido and distress," said Glenn Braunstein, MD, lead researcher and chair, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

For this 24-week, randomised, double-blind, multi-centre study, investigators enrolled 447 surgically menopausal women receiving oral oestrogen who reported low sexual desire that caused distress. The women were randomised to either a placebo patch or a transdermal testosterone patch designed to deliver 150, 200 or 450 mcg of testosterone per day. The patches were changed twice per week.

To determine the efficacy of the patches, researchers used the Sexual Activity Log (SAL) and sexual desire domain of the Profile of Female Sexual Function (PFSF) to evaluate the frequency of satisfying sexual activity. Hormone levels, adverse events and clinical laboratory results were evaluated.

Dr. Braunstein and his team found that the group receiving 300 mcg/day of testosterone reported a 30% increase in the frequency of total satisfying sexual activity compared with placebo (P<0.05), and also an 81% increase compared with their own baseline levels (P<0.05). The 150-mcg group, however, had comparable results to the placebo group. The 450-mcg group had no advantage over the 300-mcg group.

Adverse effects with testosterone were not unlike those reported with placebo, and there were minimal changes in laboratory assessments, the researchers stated.

"Low libido causing personal distress is a common finding in women who have undergone surgical removal of their ovaries. Transdermal testosterone delivers physiologic concentrations of testosterone directly to the blood stream, and this decreases the distress, [and] increases sexual activity [and] sexual desire, and is quite safe," added Dr. Braunstein.

[Study title: Testosterone Patches for the Treatment of Low Sexual Desire in Surgically Menopausal Women. Abstract P70]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities